Daré Bioscience receives Nasdaq bid price non-compliance notice

Daré Bioscience, Inc. (DARE) received a notification from the Nasdaq Stock Market on September 28, 2026, indicating that its common stock failed to meet the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company’s shares traded below the $1.00 per share threshold set by Nasdaq Listing Rule 5550(a)(2) for the preceding 30 consecutive business days.

The letter from the Listing Qualifications Department does not trigger an immediate delisting of Daré’s common stock. Instead, the company has been granted an initial compliance period of 180 calendar days, extending until March 29, 2027, to restore its share price to the required level. To resolve the deficiency during this timeframe, the closing bid price of Daré’s common stock must reach at least $1.00 for a minimum of 10 consecutive business days. If this condition is met, the Nasdaq Staff will provide written confirmation of compliance, unless it exercises discretion to extend the observation period.

Should Daré fail to regain compliance by the March 29, 2027 deadline, it may qualify for an additional 180-day compliance period. Eligibility for this extension requires the company to satisfy all other initial listing standards for the Nasdaq Capital Market, excluding the minimum bid price rule, and to meet the continued listing requirement for the market value of publicly held shares. To secure this second period, Daré must submit written notice of its intent to cure the deficiency, potentially through a reverse stock split.

If Daré is ineligible for the additional period or if the Nasdaq Staff determines that the company cannot cure the deficiency, it will issue a written notice that the common stock is subject to delisting. At that stage, Daré retains the right to appeal the delisting determination to a Nasdaq Hearing Panel. The company stated it will monitor its closing bid price and evaluate options to regain compliance, though it noted there is no assurance it will meet the minimum bid price requirement or maintain compliance with other Nasdaq listing standards. Sabrina Martucci Johnson, President and Chief Executive Officer of Daré Bioscience, Inc., signed the Form 8-K report on October 2, 2026.